UK – Rinvoq NICE approval could benefit 54,000 people

The National Institute for Health and Care Excellence has announced a new draft guidance recommending Abbvie’s Rinvoq (upadacitinib), putting the drug in the running with the company’s very own blockbuster Humira.

The treatment has been recommended as an option for severe rheumatoid arthritis (RA), a lifetime condition that can severely reduce quality of life.

Rinvoq has already been available in the US since last August, and in Europe since December, and is now making waves in the UK market. NICE currently recommends several disease-modifying anti-rheumatic drugs (DMARDs) for active severe RA, however some patients do not respond to these and welcome other options such as the Abbvie JAK1 selective inhibitor…